Sanara MedTech's CellerateRX Surgical Powder Shows $3,852 Cost Savings Per Patient in Spine Surgery Study
核心洞察
A peer-reviewed study published in the Journal of Medical Economics demonstrates that CellerateRX Surgical Powder (搜索) generates $3,852 in cost savings and 0.007 QALY gain per patient when used as an adjunct to standard care in high-risk spinal surgery.
The economic modeling study evaluated high-comorbidity patients undergoing complex spinal surgery procedures over a one-year time horizon, measuring postoperative complications, hospital readmissions, and surgical revision procedures.
Primary cost savings were attributed to the avoidance of hospital readmissions ($2,238) and surgical revision procedures ($835), with the CellerateRX treatment arm showing dominant cost-effectiveness in over 99% of clinical variability simulations.
Sanara MedTech Inc. (搜索) announced the publication of a peer-reviewed study in the Journal of Medical Economics demonstrating significant cost savings and improved health outcomes associated with CellerateRX Surgical Powder (搜索) in high-risk spinal surgery patients. The economic modeling study found that adding CellerateRX as an adjunct to standard care generated $3,852 in cost savings and a 0.007 quality-adjusted life year (QALY) gain per patient, yielding a net monetary benefit of $4,542.
Study Design and Methodology
The researchers utilized economic modeling to evaluate clinical outcomes and direct medical costs in a cohort of high-comorbidity patients undergoing complex spinal surgery procedures. Patients were classified into two treatment arms: those treated with CellerateRX as an adjunct to standard care, and those treated with standard care alone for managing acute surgical wounds (搜索) following spine surgery.
Based on published clinical literature for each treatment arm, researchers evaluated the incidence of postoperative complications, hospital readmissions, and surgical revision procedures over a one-year time horizon. Clinical efficacy was measured in quality-adjusted life years (QALYs), while direct medical costs were measured in 2025 U.S. dollars.
Cost-Effectiveness Results
The CellerateRX treatment arm exhibited a dominant cost-effectiveness profile compared to standard care alone. The primary contributors to cost savings were the avoidance of hospital readmissions and surgical revision procedures, which conservatively accounted for $2,238 and $835 of the total cost reductions, respectively.
In a probabilistic analysis conducted as part of the study, the CellerateRX treatment arm demonstrated the dominant cost-effectiveness profile compared to standard care alone in more than 99% of clinical variability simulations.
Clinical Implications
"We are pleased to see the publication of this peer-reviewed study, which represents an important addition to the compelling body of clinical evidence supporting CellerateRX's value proposition in the management of surgical wounds (搜索)," said Seth Yon, Sanara's President and Chief Executive Officer. "Its findings demonstrate the significant reductions in medical costs and improvements in health outcomes that can be achieved using CellerateRX to manage acute surgical wounds following spine surgery for high-risk patients."
The researchers concluded that CellerateRX can promote both improved health outcomes and cost savings compared to standard care alone for wound management in high-risk spinal surgery populations. They added that their findings support CellerateRX as a value-enhancing component of the spine surgery care pathway, particularly for patients with elevated complication risk.
About CellerateRX and Sanara MedTech
Sanara MedTech Inc. (搜索) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The company develops, markets and distributes surgical products for use by physicians and clinicians in hospitals, with products primarily sold in the North American surgical tissue repair market.
CellerateRX Surgical Activated Collagen Powder is part of Sanara's portfolio that includes BIASURGE Advanced Surgical Solution (搜索), FORTIFY TRG Tissue Repair Graft (搜索), and FORTIFY FLOWABLE Extracellular Matrix (搜索), as well as advanced biologic products including ACTIGEN Verified Inductive Bone Matrix (搜索), ALLOCYTE Plus Advanced Viable Bone Matrix (搜索), BiFORM Bioactive Moldable Matrix (搜索), and TEXAGEN Amniotic Membrane Allograft (搜索).